SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the FDA has approved an Investigational Device Exemption for the CardiAMP Chronic Myocardial Ischemia (CMI) Trial to treat patients with refractory angina (RA). The CardiAMP Chronic Myocardial Ischemia Trial will be […]
Coronary/Structural Heart
Mardil Medical Appoints Martin Madden to Board of Directors
MINNEAPOLIS, Jan. 29, 2018 /PRNewswire/ — Mardil Medical Inc., a privately held, clinical-stage medical device company, announced the appointment of Martin Madden to its Board of Directors. A 30-year veteran of Johnson & Johnson’s Research & Development division, Madden has unparalleled experience in bringing exceptional new products and technologies to the market. […]
CORRECTING and REPLACING First Patient Enrolled in Tryton Post Approval Study
DURHAM, N.C.–(BUSINESS WIRE)–Please replace the release dated January 24, 2018, with the following corrected version due to multiple revisions. The corrected release reads: FIRST PATIENT ENROLLED IN TRYTON POST APPROVAL STUDY The only FDA approved device to treat coronary bifurcations Tryton Medical, Inc., the leading developer of stents designed to […]
CorInnova Selected to Present at “STS/AATS Tech-Con 2018” – Sixth Honor in Five Months
HOUSTON–(BUSINESS WIRE)– CorInnova, an emerging medical device company developing breakthrough technology for the treatment of Heart Failure, announced today that it has been selected to present at the Society for Thoracic Surgeons (STS) / American Association for Thoracic Surgery (AATS) Tech-Con 2018 event to be held this coming Saturday, Jan. 27, […]
REVA Announces First Implant of the Fantom Bioresorbable Scaffold in Italy
SAN DIEGO, Jan. 24, 2018 (GLOBE NEWSWIRE) — REVA Medical Inc.(ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the first implant of the Fantom bioresorbable scaffold (“BRS”) in Italy. The procedure was conducted by Dr. Bernardo Cortese at the Fatebenefratelli Hospital in Milan. “Fantom […]
Boston Scientific Announces Investment and Acquisition Option Agreement with Millipede, Inc.
MARLBOROUGH, Mass., Jan. 24, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has closed an investment and entered into an acquisition option agreement with Millipede, Inc., a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation (MR). Under the terms of the […]
Corindus to Co-Sponsor Courses at Multiple Leading Healthcare Institutions on Value-based Interventional Procedural Training
WALTHAM, Mass.–(BUSINESS WIRE)– Corindus Vascular Robotics (NYSE American: CVRS), a leading developer of precision vascular robotics, announced it will co-sponsor courses at multiple leading hospitals to educate interventional cardiologists on transradial access techniques and robotic-assisted vascular interventions. The course series entitled “Complex Radial Interventions on Robotic and Manual Platforms” is designed to […]
NeoChord Announces a Research Collaboration With the Skirball Center for Innovation at the Cardiovascular Research Foundation
ST. LOUIS PARK, Minn., Jan. 22, 2018 (GLOBE NEWSWIRE) — NeoChord, a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced a research collaboration with the Skirball Center for Innovation (SCI) at the Cardiovascular Research Foundation (CRF)to accelerate development of the company’s transcatheter […]
Cardiome Announces Expanded Label for Aggrastat in China Including New STEMI Indication and High Dose Bolus Regimen
VANCOUVER, Jan. 23, 2018 /PRNewswire/ – Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that the Chinese Center for Drug Evaluation (CDE) has approved an expansion of the indications for Aggrastat (tirofiban hydrochloride) to now, in addition to acute coronary syndromes […]
Neovasc Names Former BeneChill CEO as New Leader
VANCOUVER, Jan. 22, 2018 /PRNewswire/ – Neovasc (“Neovasc” or the “Company“) (Nasdaq, TSX: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the “Board”) has appointed Fred A. Colen as president and chief executive officer effective immediately. This leadership transition is a key element […]



